The Comparison of Lidocaine Metabolism in Normal- and Dys-Function of Liver on Rat Liver Perfusion Model

Abstract

Lidocaine(LID), an antiarrhythmic agent, is used as a first-line agent for acute severe ventricular arrhythmias. LID is often used emergently without assessment of liver function. We examined the pharmacokinetic parameters of LID and monoethylglycinexylidide(MEGX) in normal- and dys-function of liver using the perfused rat liver. The liver function was normal range within 30 minutes of starting perfusion, but hepatic dysfunction was appeared at 150 minutes after starting perfusion. So we used LID(3mg/kg) at 30 and 150 minutes of starting perfusion. AUC_MEGX is significantly increased at 150 minutes, except for AUC_LID, CL_LID, and CL_MEGX. These results showed the possibility that the elimination of MEGX may be delayed in hepatic dysfunction. And it is suggested that LID can be injected with the same dose in normal- and dys-function of liver.